| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 53 | 2023 | 467 | 10.630 |
Why?
|
| Heart Arrest | 27 | 2020 | 328 | 5.000 |
Why?
|
| Coronary Artery Disease | 23 | 2022 | 678 | 4.450 |
Why?
|
| Myocardial Infarction | 32 | 2023 | 1014 | 4.430 |
Why?
|
| Cardiopulmonary Resuscitation | 22 | 2022 | 261 | 3.810 |
Why?
|
| Hospitals | 18 | 2021 | 632 | 3.790 |
Why?
|
| United States Department of Veterans Affairs | 20 | 2022 | 637 | 3.470 |
Why?
|
| Registries | 51 | 2025 | 1884 | 3.030 |
Why?
|
| Coronary Angiography | 12 | 2023 | 306 | 2.330 |
Why?
|
| Hospitalization | 23 | 2025 | 2077 | 2.170 |
Why?
|
| Practice Patterns, Physicians' | 13 | 2021 | 1269 | 2.140 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 6 | 2021 | 86 | 2.050 |
Why?
|
| Myocardial Ischemia | 5 | 2022 | 249 | 1.980 |
Why?
|
| Cardiovascular Diseases | 15 | 2025 | 2024 | 1.920 |
Why?
|
| Guideline Adherence | 10 | 2021 | 525 | 1.900 |
Why?
|
| Veterans | 15 | 2022 | 1419 | 1.890 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2020 | 45 | 1.790 |
Why?
|
| United States | 82 | 2025 | 13938 | 1.780 |
Why?
|
| Patient Selection | 11 | 2020 | 665 | 1.740 |
Why?
|
| Aged | 96 | 2025 | 22083 | 1.740 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2023 | 440 | 1.650 |
Why?
|
| Health Status | 8 | 2020 | 751 | 1.570 |
Why?
|
| Coronary Artery Bypass | 6 | 2021 | 222 | 1.560 |
Why?
|
| Hospitals, Veterans | 7 | 2020 | 257 | 1.510 |
Why?
|
| Cardiology | 10 | 2024 | 267 | 1.490 |
Why?
|
| Aortic Valve Stenosis | 8 | 2022 | 218 | 1.490 |
Why?
|
| Middle Aged | 88 | 2025 | 31074 | 1.430 |
Why?
|
| Exercise Test | 5 | 2022 | 615 | 1.420 |
Why?
|
| Time Factors | 44 | 2025 | 6518 | 1.420 |
Why?
|
| Hospital Costs | 6 | 2020 | 117 | 1.400 |
Why?
|
| Hypothermia, Induced | 4 | 2021 | 73 | 1.390 |
Why?
|
| Hospital Mortality | 20 | 2023 | 844 | 1.370 |
Why?
|
| Humans | 172 | 2025 | 129116 | 1.330 |
Why?
|
| Quality Indicators, Health Care | 10 | 2024 | 297 | 1.320 |
Why?
|
| Risk Assessment | 22 | 2021 | 3260 | 1.290 |
Why?
|
| Treatment Outcome | 48 | 2025 | 10226 | 1.230 |
Why?
|
| Male | 112 | 2025 | 63194 | 1.220 |
Why?
|
| Risk Factors | 50 | 2025 | 9767 | 1.190 |
Why?
|
| Female | 110 | 2025 | 68510 | 1.150 |
Why?
|
| Angina, Stable | 3 | 2019 | 17 | 1.140 |
Why?
|
| Ventricular Fibrillation | 5 | 2018 | 58 | 1.140 |
Why?
|
| Healthcare Disparities | 6 | 2021 | 581 | 1.070 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2018 | 36 | 1.050 |
Why?
|
| Patient Identification Systems | 3 | 2016 | 16 | 1.030 |
Why?
|
| Tachycardia, Ventricular | 5 | 2018 | 169 | 1.010 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2018 | 239 | 0.990 |
Why?
|
| ST Elevation Myocardial Infarction | 7 | 2022 | 52 | 0.980 |
Why?
|
| Electric Countershock | 6 | 2018 | 106 | 0.980 |
Why?
|
| Quality Improvement | 10 | 2021 | 1099 | 0.980 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 295 | 0.970 |
Why?
|
| Transcatheter Aortic Valve Replacement | 6 | 2022 | 117 | 0.970 |
Why?
|
| Angina Pectoris | 3 | 2015 | 67 | 0.940 |
Why?
|
| Retrospective Studies | 50 | 2025 | 14571 | 0.930 |
Why?
|
| Heart Diseases | 4 | 2024 | 347 | 0.930 |
Why?
|
| Stroke | 12 | 2023 | 1067 | 0.910 |
Why?
|
| Hydroxychloroquine | 2 | 2021 | 55 | 0.890 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2015 | 138 | 0.880 |
Why?
|
| Aged, 80 and over | 33 | 2025 | 7064 | 0.880 |
Why?
|
| Patient Discharge | 12 | 2025 | 857 | 0.880 |
Why?
|
| Decision Support Techniques | 7 | 2020 | 405 | 0.860 |
Why?
|
| Achilles Tendon | 1 | 2024 | 41 | 0.860 |
Why?
|
| Guidelines as Topic | 3 | 2021 | 261 | 0.850 |
Why?
|
| Length of Stay | 10 | 2025 | 1123 | 0.830 |
Why?
|
| Radial Artery | 5 | 2017 | 69 | 0.830 |
Why?
|
| American Heart Association | 14 | 2025 | 309 | 0.820 |
Why?
|
| Practice Guidelines as Topic | 10 | 2019 | 1493 | 0.810 |
Why?
|
| Coronary Disease | 4 | 2020 | 384 | 0.800 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 64 | 0.790 |
Why?
|
| Heart Failure | 6 | 2021 | 2158 | 0.750 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2020 | 11 | 0.730 |
Why?
|
| Rural Health | 1 | 2021 | 70 | 0.720 |
Why?
|
| Coronary Stenosis | 2 | 2017 | 39 | 0.700 |
Why?
|
| Acute Coronary Syndrome | 5 | 2019 | 267 | 0.700 |
Why?
|
| Program Evaluation | 6 | 2021 | 876 | 0.690 |
Why?
|
| Odds Ratio | 12 | 2021 | 1025 | 0.670 |
Why?
|
| Preoperative Care | 2 | 2021 | 342 | 0.670 |
Why?
|
| Unnecessary Procedures | 3 | 2015 | 48 | 0.660 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 369 | 0.650 |
Why?
|
| Coronavirus | 1 | 2020 | 43 | 0.650 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 386 | 0.650 |
Why?
|
| Emergency Medical Services | 6 | 2022 | 550 | 0.640 |
Why?
|
| Time-to-Treatment | 6 | 2020 | 180 | 0.640 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 490 | 0.640 |
Why?
|
| Preventive Health Services | 1 | 2021 | 145 | 0.640 |
Why?
|
| Smartphone | 1 | 2020 | 88 | 0.640 |
Why?
|
| Quality of Health Care | 5 | 2016 | 608 | 0.640 |
Why?
|
| Aortic Valve | 5 | 2022 | 350 | 0.620 |
Why?
|
| Airway Management | 1 | 2019 | 44 | 0.620 |
Why?
|
| Insurance, Health | 2 | 2021 | 271 | 0.620 |
Why?
|
| Hypertension | 4 | 2023 | 1243 | 0.620 |
Why?
|
| Atrial Fibrillation | 6 | 2025 | 379 | 0.620 |
Why?
|
| Pneumonia, Viral | 5 | 2021 | 342 | 0.610 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 282 | 0.610 |
Why?
|
| Echocardiography, Doppler | 2 | 2021 | 110 | 0.610 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 173 | 0.590 |
Why?
|
| Anticoagulants | 5 | 2025 | 614 | 0.590 |
Why?
|
| Follow-Up Studies | 13 | 2021 | 4915 | 0.580 |
Why?
|
| Physical Fitness | 1 | 2019 | 203 | 0.580 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 317 | 0.570 |
Why?
|
| Resuscitation | 2 | 2019 | 240 | 0.570 |
Why?
|
| Transportation of Patients | 2 | 2018 | 50 | 0.560 |
Why?
|
| Cohort Studies | 18 | 2024 | 5407 | 0.560 |
Why?
|
| Cardiovascular Agents | 4 | 2018 | 152 | 0.560 |
Why?
|
| Aspirin | 7 | 2023 | 378 | 0.550 |
Why?
|
| Hemorrhage | 11 | 2023 | 645 | 0.550 |
Why?
|
| Predictive Value of Tests | 11 | 2020 | 1943 | 0.550 |
Why?
|
| Health Care Costs | 2 | 2019 | 395 | 0.540 |
Why?
|
| Survival Rate | 9 | 2020 | 1875 | 0.540 |
Why?
|
| Natural Language Processing | 1 | 2018 | 94 | 0.540 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2016 | 22 | 0.540 |
Why?
|
| Elective Surgical Procedures | 4 | 2018 | 163 | 0.540 |
Why?
|
| Incidence | 11 | 2021 | 2635 | 0.530 |
Why?
|
| Logistic Models | 12 | 2020 | 1979 | 0.530 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2022 | 68 | 0.530 |
Why?
|
| Patient Care Planning | 1 | 2016 | 149 | 0.500 |
Why?
|
| Mortality | 7 | 2021 | 308 | 0.500 |
Why?
|
| Cardiologists | 3 | 2024 | 46 | 0.500 |
Why?
|
| Comorbidity | 10 | 2021 | 1546 | 0.490 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 246 | 0.490 |
Why?
|
| Medication Errors | 1 | 2016 | 96 | 0.490 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 894 | 0.490 |
Why?
|
| Assisted Circulation | 1 | 2015 | 25 | 0.490 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 338 | 0.480 |
Why?
|
| Electrocardiography | 4 | 2021 | 607 | 0.480 |
Why?
|
| Medicare | 9 | 2021 | 724 | 0.480 |
Why?
|
| Chi-Square Distribution | 8 | 2018 | 513 | 0.460 |
Why?
|
| Secondary Prevention | 5 | 2023 | 220 | 0.450 |
Why?
|
| Resuscitation Orders | 3 | 2020 | 46 | 0.450 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 206 | 0.450 |
Why?
|
| Risk Adjustment | 4 | 2020 | 79 | 0.440 |
Why?
|
| Forecasting | 3 | 2020 | 358 | 0.430 |
Why?
|
| Myocardial Revascularization | 3 | 2019 | 69 | 0.430 |
Why?
|
| Myocardial Reperfusion | 1 | 2013 | 50 | 0.430 |
Why?
|
| Health Services Accessibility | 3 | 2018 | 897 | 0.420 |
Why?
|
| Postoperative Complications | 4 | 2019 | 2496 | 0.420 |
Why?
|
| Washington | 5 | 2018 | 148 | 0.420 |
Why?
|
| Health Promotion | 1 | 2019 | 717 | 0.420 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 317 | 0.420 |
Why?
|
| Disease Management | 1 | 2017 | 593 | 0.410 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 294 | 0.410 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 87 | 0.390 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 5376 | 0.390 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 647 | 0.390 |
Why?
|
| Sleep Deprivation | 3 | 2019 | 171 | 0.380 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 263 | 0.380 |
Why?
|
| Patient Readmission | 8 | 2019 | 668 | 0.380 |
Why?
|
| Atherosclerosis | 3 | 2024 | 410 | 0.370 |
Why?
|
| Telemedicine | 1 | 2020 | 783 | 0.370 |
Why?
|
| Coronary Occlusion | 2 | 2023 | 18 | 0.360 |
Why?
|
| Anesthesiology | 2 | 2024 | 45 | 0.360 |
Why?
|
| Clinical Decision-Making | 5 | 2019 | 305 | 0.340 |
Why?
|
| Survival Analysis | 6 | 2019 | 1265 | 0.340 |
Why?
|
| Communication Barriers | 1 | 2011 | 100 | 0.330 |
Why?
|
| Hemofiltration | 1 | 2009 | 22 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2024 | 413 | 0.330 |
Why?
|
| Cardiology Service, Hospital | 2 | 2020 | 27 | 0.330 |
Why?
|
| Severity of Illness Index | 11 | 2021 | 2739 | 0.320 |
Why?
|
| Echocardiography | 5 | 2024 | 627 | 0.320 |
Why?
|
| Medical Futility | 2 | 2019 | 24 | 0.310 |
Why?
|
| Betacoronavirus | 3 | 2020 | 252 | 0.310 |
Why?
|
| Shock, Cardiogenic | 3 | 2020 | 59 | 0.310 |
Why?
|
| Bundle-Branch Block | 2 | 2019 | 30 | 0.310 |
Why?
|
| Databases, Factual | 7 | 2019 | 1279 | 0.300 |
Why?
|
| Quality of Life | 3 | 2020 | 2693 | 0.300 |
Why?
|
| Referral and Consultation | 3 | 2018 | 732 | 0.300 |
Why?
|
| Sleep | 3 | 2019 | 676 | 0.290 |
Why?
|
| Exercise | 1 | 2019 | 1947 | 0.290 |
Why?
|
| Centralized Hospital Services | 2 | 2018 | 6 | 0.280 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 5068 | 0.270 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1973 | 0.270 |
Why?
|
| Aortic Aneurysm | 2 | 2024 | 64 | 0.270 |
Why?
|
| Drug Utilization Review | 2 | 2016 | 56 | 0.260 |
Why?
|
| Health Status Disparities | 2 | 2020 | 256 | 0.260 |
Why?
|
| Prognosis | 5 | 2020 | 3788 | 0.260 |
Why?
|
| Intensive Care Units | 2 | 2021 | 719 | 0.260 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 832 | 0.250 |
Why?
|
| Depression | 1 | 2015 | 1292 | 0.250 |
Why?
|
| Pandemics | 7 | 2023 | 1491 | 0.250 |
Why?
|
| Intubation, Intratracheal | 2 | 2019 | 241 | 0.250 |
Why?
|
| Prospective Studies | 8 | 2023 | 7079 | 0.240 |
Why?
|
| Adult | 18 | 2024 | 35510 | 0.240 |
Why?
|
| Veterans Health | 2 | 2018 | 175 | 0.240 |
Why?
|
| Aorta | 2 | 2024 | 407 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2023 | 1735 | 0.230 |
Why?
|
| Cost Savings | 3 | 2019 | 79 | 0.230 |
Why?
|
| Heel | 1 | 2024 | 11 | 0.230 |
Why?
|
| Lipoprotein(a) | 1 | 2024 | 67 | 0.220 |
Why?
|
| Warfarin | 3 | 2022 | 147 | 0.220 |
Why?
|
| Rupture | 1 | 2024 | 100 | 0.220 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 774 | 0.220 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2023 | 45 | 0.210 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 3033 | 0.210 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 528 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2017 | 749 | 0.200 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 361 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2024 | 139 | 0.200 |
Why?
|
| Liver Transplantation | 1 | 2010 | 799 | 0.200 |
Why?
|
| Blood Pressure Determination | 1 | 2023 | 150 | 0.200 |
Why?
|
| Health Equity | 1 | 2024 | 82 | 0.200 |
Why?
|
| Medication Adherence | 3 | 2021 | 569 | 0.190 |
Why?
|
| Bed Occupancy | 1 | 2021 | 13 | 0.190 |
Why?
|
| Data Accuracy | 1 | 2022 | 59 | 0.190 |
Why?
|
| Technology Transfer | 1 | 2021 | 11 | 0.190 |
Why?
|
| Hospital Bed Capacity | 1 | 2021 | 24 | 0.190 |
Why?
|
| Patient Care Team | 2 | 2018 | 602 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2025 | 332 | 0.190 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 127 | 0.190 |
Why?
|
| Diagnosis-Related Groups | 1 | 2020 | 27 | 0.180 |
Why?
|
| Cardiac Catheterization | 3 | 2019 | 515 | 0.180 |
Why?
|
| Insurance Carriers | 1 | 2021 | 11 | 0.180 |
Why?
|
| Embolic Protection Devices | 1 | 2021 | 12 | 0.180 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 62 | 0.180 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2021 | 27 | 0.180 |
Why?
|
| Hospitals, Public | 1 | 2020 | 26 | 0.180 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 1496 | 0.180 |
Why?
|
| Heart Valve Prosthesis | 1 | 2022 | 111 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 1363 | 0.170 |
Why?
|
| Chloroquine | 1 | 2020 | 52 | 0.170 |
Why?
|
| Heart | 1 | 2024 | 639 | 0.170 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2021 | 130 | 0.170 |
Why?
|
| Health Facility Size | 2 | 2017 | 11 | 0.170 |
Why?
|
| Triage | 2 | 2021 | 213 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 142 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2019 | 648 | 0.160 |
Why?
|
| Publishing | 1 | 2021 | 141 | 0.160 |
Why?
|
| Ischemia | 1 | 2022 | 395 | 0.160 |
Why?
|
| Health Services Research | 2 | 2012 | 389 | 0.160 |
Why?
|
| Patient Safety | 3 | 2018 | 291 | 0.160 |
Why?
|
| Environment | 1 | 2021 | 347 | 0.160 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1210 | 0.160 |
Why?
|
| Pulse | 1 | 2018 | 27 | 0.160 |
Why?
|
| Electronic Health Records | 4 | 2021 | 976 | 0.150 |
Why?
|
| Life Style | 1 | 2021 | 460 | 0.150 |
Why?
|
| Pacemaker, Artificial | 1 | 2019 | 109 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2019 | 63 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 22 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2019 | 59 | 0.150 |
Why?
|
| Mitral Valve | 1 | 2019 | 86 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2024 | 492 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 39 | 0.150 |
Why?
|
| Inpatients | 2 | 2020 | 464 | 0.150 |
Why?
|
| Heart Injuries | 1 | 2018 | 36 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2018 | 56 | 0.150 |
Why?
|
| Treatment Refusal | 1 | 2018 | 87 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2019 | 328 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 201 | 0.150 |
Why?
|
| Contrast Media | 1 | 2020 | 388 | 0.150 |
Why?
|
| Research Design | 2 | 2021 | 1040 | 0.140 |
Why?
|
| Drug Users | 1 | 2018 | 42 | 0.140 |
Why?
|
| Echocardiography, Stress | 1 | 2017 | 20 | 0.140 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 27 | 0.140 |
Why?
|
| Vascular System Injuries | 1 | 2018 | 73 | 0.140 |
Why?
|
| Prevalence | 4 | 2020 | 2564 | 0.140 |
Why?
|
| Inservice Training | 1 | 2018 | 111 | 0.140 |
Why?
|
| Subacute Care | 1 | 2018 | 77 | 0.140 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 81 | 0.140 |
Why?
|
| Documentation | 1 | 2019 | 182 | 0.140 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 134 | 0.140 |
Why?
|
| Early Diagnosis | 2 | 2015 | 236 | 0.140 |
Why?
|
| Work Schedule Tolerance | 1 | 2017 | 42 | 0.140 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 89 | 0.140 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 124 | 0.140 |
Why?
|
| Radiologists | 1 | 2017 | 41 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 2 | 2018 | 128 | 0.140 |
Why?
|
| Disease Progression | 5 | 2024 | 2613 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 566 | 0.140 |
Why?
|
| Clinical Competence | 3 | 2019 | 1021 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 108 | 0.140 |
Why?
|
| Linear Models | 3 | 2017 | 816 | 0.140 |
Why?
|
| Patient Admission | 1 | 2018 | 184 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2016 | 319 | 0.140 |
Why?
|
| Cardiac Rehabilitation | 1 | 2017 | 35 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2017 | 984 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 124 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 111 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2018 | 236 | 0.130 |
Why?
|
| Coronary Thrombosis | 1 | 2016 | 23 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2019 | 337 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2017 | 102 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2023 | 647 | 0.130 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 104 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 89 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2018 | 558 | 0.130 |
Why?
|
| Contraindications | 1 | 2016 | 88 | 0.130 |
Why?
|
| Crowdsourcing | 1 | 2016 | 18 | 0.130 |
Why?
|
| Off-Label Use | 1 | 2016 | 51 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 458 | 0.130 |
Why?
|
| Drug Labeling | 1 | 2016 | 40 | 0.130 |
Why?
|
| Lipids | 1 | 2020 | 624 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 122 | 0.130 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 70 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2016 | 304 | 0.130 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 90 | 0.120 |
Why?
|
| Workload | 1 | 2017 | 152 | 0.120 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 16 | 0.120 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 322 | 0.120 |
Why?
|
| Cell Phone | 1 | 2016 | 70 | 0.120 |
Why?
|
| Obesity | 2 | 2021 | 2863 | 0.120 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 11 | 0.120 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 281 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 424 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 330 | 0.120 |
Why?
|
| Ethics, Research | 1 | 2015 | 30 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2019 | 209 | 0.120 |
Why?
|
| Models, Organizational | 1 | 2015 | 145 | 0.120 |
Why?
|
| Occupational Health | 1 | 2017 | 196 | 0.110 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2014 | 6 | 0.110 |
Why?
|
| Telephone | 1 | 2015 | 169 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2014 | 16 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 79 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3342 | 0.110 |
Why?
|
| Andropause | 1 | 2013 | 5 | 0.110 |
Why?
|
| Monte Carlo Method | 2 | 2015 | 138 | 0.110 |
Why?
|
| Antithrombins | 1 | 2014 | 53 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 187 | 0.110 |
Why?
|
| Pediatrics | 1 | 2022 | 1062 | 0.110 |
Why?
|
| Social Media | 1 | 2016 | 139 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 393 | 0.110 |
Why?
|
| Polymers | 1 | 2017 | 473 | 0.100 |
Why?
|
| Epinephrine | 1 | 2013 | 138 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2014 | 158 | 0.100 |
Why?
|
| Medicaid | 1 | 2017 | 437 | 0.100 |
Why?
|
| Burnout, Professional | 1 | 2019 | 408 | 0.100 |
Why?
|
| Language | 1 | 2015 | 284 | 0.100 |
Why?
|
| Regional Health Planning | 1 | 2012 | 7 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1209 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 427 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2016 | 626 | 0.100 |
Why?
|
| Advanced Cardiac Life Support | 2 | 2022 | 27 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2021 | 759 | 0.090 |
Why?
|
| Chest Wall Oscillation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2018 | 1230 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 1004 | 0.090 |
Why?
|
| Multilingualism | 1 | 2011 | 26 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2016 | 2266 | 0.090 |
Why?
|
| Peptides | 1 | 2016 | 911 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 2715 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2017 | 723 | 0.090 |
Why?
|
| Testosterone | 1 | 2013 | 379 | 0.080 |
Why?
|
| Diuretics | 1 | 2009 | 74 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1359 | 0.080 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 19 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 767 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 385 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 287 | 0.080 |
Why?
|
| Dabigatran | 2 | 2021 | 21 | 0.070 |
Why?
|
| Sex Factors | 3 | 2021 | 1953 | 0.070 |
Why?
|
| Propensity Score | 2 | 2021 | 265 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 718 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 1013 | 0.070 |
Why?
|
| California | 2 | 2019 | 400 | 0.070 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 493 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 968 | 0.070 |
Why?
|
| Angina, Unstable | 2 | 2017 | 77 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2017 | 243 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 5739 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 864 | 0.060 |
Why?
|
| Biomarkers | 3 | 2024 | 3896 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2015 | 1641 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 856 | 0.060 |
Why?
|
| Academies and Institutes | 1 | 2024 | 48 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 2437 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 758 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2024 | 146 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2475 | 0.050 |
Why?
|
| Peer Review, Research | 1 | 2023 | 41 | 0.050 |
Why?
|
| Thrombosis | 2 | 2016 | 323 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 3120 | 0.050 |
Why?
|
| Anesthesiologists | 1 | 2022 | 12 | 0.050 |
Why?
|
| Stents | 2 | 2017 | 504 | 0.050 |
Why?
|
| Civil Defense | 1 | 2021 | 18 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 58 | 0.050 |
Why?
|
| Vital Signs | 1 | 2021 | 41 | 0.050 |
Why?
|
| Organ Size | 1 | 2021 | 441 | 0.040 |
Why?
|
| Thiazoles | 1 | 2021 | 115 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 80 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 80 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 88 | 0.040 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 84 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2541 | 0.040 |
Why?
|
| Dyspnea | 1 | 2021 | 239 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 51 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 650 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 160 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 12389 | 0.040 |
Why?
|
| Research Personnel | 1 | 2021 | 160 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2021 | 246 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 261 | 0.040 |
Why?
|
| Self Concept | 1 | 2021 | 239 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2021 | 254 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 144 | 0.040 |
Why?
|
| Transitional Care | 1 | 2018 | 37 | 0.040 |
Why?
|
| After-Hours Care | 1 | 2018 | 14 | 0.040 |
Why?
|
| Ventricular Flutter | 1 | 2017 | 1 | 0.040 |
Why?
|
| Minnesota | 1 | 2018 | 148 | 0.040 |
Why?
|
| Population Growth | 1 | 2017 | 9 | 0.040 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2017 | 8 | 0.040 |
Why?
|
| Punctures | 1 | 2017 | 40 | 0.040 |
Why?
|
| F Factor | 1 | 2017 | 3 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 590 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 405 | 0.040 |
Why?
|
| Family Practice | 1 | 2021 | 435 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 477 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 147 | 0.040 |
Why?
|
| Child | 3 | 2022 | 20805 | 0.030 |
Why?
|
| Blood Circulation | 1 | 2017 | 40 | 0.030 |
Why?
|
| Angiography | 1 | 2017 | 192 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 638 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2023 | 1706 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 544 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 362 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2017 | 107 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 184 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 128 | 0.030 |
Why?
|
| Defibrillators | 1 | 2016 | 17 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1945 | 0.030 |
Why?
|
| Computers | 1 | 2016 | 65 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 258 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2017 | 187 | 0.030 |
Why?
|
| Research Report | 1 | 2016 | 73 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 66 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 139 | 0.030 |
Why?
|
| Public Health | 1 | 2020 | 486 | 0.030 |
Why?
|
| Health Personnel | 1 | 2021 | 649 | 0.030 |
Why?
|
| Utilization Review | 1 | 2015 | 37 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 348 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 582 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 33 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2017 | 293 | 0.030 |
Why?
|
| Scientific Misconduct | 1 | 2015 | 12 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 616 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 116 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 220 | 0.030 |
Why?
|
| Manikins | 1 | 2014 | 23 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1271 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 240 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 34600 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1621 | 0.020 |
Why?
|
| Palliative Care | 1 | 2018 | 721 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 86 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1003 | 0.020 |
Why?
|
| Hospital Administration | 1 | 2011 | 21 | 0.020 |
Why?
|
| Overweight | 1 | 2016 | 526 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 250 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 20301 | 0.020 |
Why?
|
| Mental Health | 1 | 2017 | 684 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2015 | 506 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3383 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 1098 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 324 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2018 | 2096 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 1209 | 0.020 |
Why?
|